CCAR2 and familial pancreatic carcinoma: The sensitivity of pancreatic cancer cells to the Sirt1/2 inhibitor Tenovin-6 correlates with the levels of SIRT1/Dbc1 suggesting that Dbc1 can be a biomarker for those pancreatic tumors that could benefit from SIRT1-inhibitory drugs (174).